InsidersTradesSigma
Total declarations
Companies
▲ Purchases (5 ops.)
▼ Sales (0 ops.)
Insider track record
OtherDisclosed buys
5
Disclosed sells
0
T+90 hit rate
33%
T+90 mean return
+0.0%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by Berman Robert Andrew. Director active across 2 companies, notably Hancock Jaffe Laboratories, Inc.. Aggregated, 6 disclosures have been logged. Breakdown: 5 buys · 0 sell. Total volume traded: €79k. Activity tracked since 18 May 2021. The latest transaction was filed on 19 December 2024 (Acquisition). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Berman Robert Andrew
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations6 total
12,000 shares@ US$2.5532.0% of flowCommon StockSEC:0001493152-24-050865:0
Canonical exit: 19 Mar 2025 (T+90)
2,500 shares@ US$3.800.14% mcap14.3% of flowCommon StockSEC:0001493152-22-017957:0
Canonical exit: 25 Sept 2022 (T+90)
200,000 sharesCommon StockSEC:0001493152-21-030335:0
2,000 shares@ US$7.4320.0% of flowCommon StockSEC:0001493152-21-029430:0
Canonical exit: 17 Feb 2022 (T+90)
2,000 shares@ US$7.8721.2% of flowCommon StockSEC:0001493152-21-029229:0
Canonical exit: 14 Feb 2022 (T+90)
3,000 shares@ US$5.47100.0% of flowCommon Stock, $0.00001 par valueSEC:0001493152-21-012298:0
Canonical exit: 16 Aug 2021 (T+90)
6 of 6 declarations
About Berman Robert Andrew
Robert Andrew Berman is a director at Hancock Jaffe Laboratories, Inc. and enVVeno Medical Corp.
